Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Bendamustine Bridging to Auto-HSCT in Pediatric R/R Hodgkin Lymphoma
NCT06931613Phase 2Enrolling by invitation
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Jun 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Hodgkin lymphoma (HL), sponsored by First Saint Petersburg State Medical University. Started Jun 2022; status: enrolling by invitation.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT06931613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931613.